利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.029 秒)

    OXIME AND/OR HYDRAZONE CONTAINING NITROSATED AND/OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE
    1.
    发明公开
    OXIME AND/OR HYDRAZONE CONTAINING NITROSATED AND/OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE 审中-公开
    肟和/或HYDRAZONHALTIGE，NITRO镀锌和/或亚硝基化环氧合酶-2选择性抑制剂，组合物和使用方法

    公开(公告)号：EP1539679A2

    公开(公告)日：2005-06-15

    申请号：EP03742299.5

    申请日：2003-06-30

    申请人： Nitromed, Inc.

    发明人： GARVEY, David, S. ,  RANATUNGE, Ramani, R. ,  RICHARDSON, Stewart, K.

    IPC分类号： C07C251/32 ,  C07C251/72

    CPC分类号： C07D231/12

    摘要： The invention describes novel cyclooxygenase 2(COX-2) selective inhibitors having at least one oxime group or hydrazone group and novel compositions comprising at least one cyclooxigenase 2(COX-2) selective inhibitor having at least one oxime group or hydrazone group, and optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor having at least one oxime group or hydrazone group, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxigenase 2 selective inhibitors of the invention having at least one oxime group or hydrazone group can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxigenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

    NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    2.
    发明公开
    NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
    NITRO和镀锌亚硝基化合物，组合物及其应用

    公开(公告)号：EP1603933A2

    公开(公告)日：2005-12-14

    申请号：EP04749385.3

    申请日：2004-03-15

    申请人： Nitromed, Inc.

    发明人： EARL, Richard, A. ,  GARVEY, David, S. ,  GASTON, Ricky, D. ,  LIN, Chia-En ,  RANATUNGE, Ramani, R. ,  RICHARDSON, Stewart, K. ,  STEVENSON, Cheri, A.

    IPC分类号： C07J1/00 ,  C07J17/00 ,  C07J43/00 ,  A61K31/56 ,  A61K31/58

    CPC分类号： C07J17/00 ,  C07J1/00 ,  C07J31/006 ,  C07J41/0044 ,  C07J43/00 ,  C07J43/003

    摘要： The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and at least one nitric oxide donor compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering at least one compound of the invention that is optionally nitrosated and/or nitrosylated, in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The compounds of the invention are preferably estradiol compounds, troglitazone compounds, tranilast compounds, retinoic acid compounds, resveratol compounds, myophenolic acid compounds, acid compounds, anthracenone compounds and trapidil compounds.

    CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE
    3.
    发明公开
    CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE 审中-公开
    环氧化酶2选择性抑制剂，组合物及其使用方法

    公开(公告)号：EP1542972A2

    公开(公告)日：2005-06-22

    申请号：EP03772004.2

    申请日：2003-07-29

    申请人： Nitromed, Inc.

    发明人： GARVEY, David, S. ,  KHANAPURE, Subhash, P. ,  RANATUNGE, Ramani, R. ,  RICHARDSON, Stewart, K. ,  SCHROEDER, Joseph, D.

    IPC分类号： C07D207/325 ,  C07D231/06 ,  C07D237/14 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04 ,  A61K31/40 ,  A61K31/415 ,  A61K31/4155 ,  A61P29/00

    CPC分类号： C07D213/55 ,  C07D213/50 ,  C07D231/12 ,  C07D231/14

    摘要： The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium­derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

    CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE
    4.
    发明公开
    CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE 审中-公开
    CYCLOOXGENASE-2选择性抑制剂，组合物和使用方法

    公开(公告)号：EP1534683A2

    公开(公告)日：2005-06-01

    申请号：EP03762000.2

    申请日：2003-06-25

    申请人： Nitromed, Inc.

    发明人： BANDARAGE, Upul, K. ,  EARL, Richard, A. ,  EZAWA, Maiko ,  FANG, Xinqin ,  GARVEY, David, S. ,  KHANAPURE, Subhash, P. ,  RANATUNGE, Ramani, R. ,  RICHARDSON, Stewart, K. ,  SCHROEDER, Joseph, D. ,  STEVENSON, Cheri, A. ,  WEY, Shiow-Jyi

    IPC分类号： C07D231/12 ,  A61K31/415

    CPC分类号： C07D231/12 ,  C07D261/08 ,  C07D401/04

    摘要： The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

    摘要翻译： 本发明描述了新型环加氧酶2（COX-2）选择性抑制剂和包含至少一种环氧合酶2（COX-2）选择性抑制剂和任选地至少一种捐赠，转移或释放一氧化氮的化合物的新组合物，刺激内源性合成 的一氧化氮，提高内源性内皮细胞衍生的松弛因子的水平，或者是一氧化氮合酶的底物，和/或至少一种治疗剂。 本发明还提供了包含至少一种选择性抑制剂（任选亚硝化和/或亚硝基化）和任选地至少一种一氧化氮供体和/或任选地至少一种治疗剂的新型试剂盒。 本发明的新型环加氧酶2选择性抑制剂可以任选地亚硝化和/或亚硝基化。 本发明还提供治疗炎症，疼痛和发热的方法; 用于治疗和/或改善COX-2选择性抑制剂的胃肠道特性; 用于促进伤口愈合; 用于治疗和/或预防肾和/或呼吸毒性; 用于治疗和/或预防由环氧合酶-2水平升高引起的其他疾病; 并用于改善COX-2选择性抑制剂的心血管特征。

    NITRIC OXIDE ENHANCING ANGIOTENSIN II ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    5.
    发明公开
    NITRIC OXIDE ENHANCING ANGIOTENSIN II ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
    氮氧化物加固拮抗血管紧张素II化合物，组合物及使用方法

    公开(公告)号：EP1922069A2

    公开(公告)日：2008-05-21

    申请号：EP06800882.0

    申请日：2006-08-07

    申请人： Nitromed, Inc.

    发明人： GARVEY, David, S. ,  CAI, Xiong ,  FANG, Xinqin ,  RANATUNGE, Ramani, R. ,  WEY, Shiow-Jyi ,  ZHAI, Hai-Xiao

    IPC分类号： A61K31/4245 ,  A61K31/433 ,  A61K31/42

    CPC分类号： C07D257/04 ,  C07D401/12 ,  C07D403/10 ,  C07D403/12 ,  C07D471/04

    摘要： The invention describes compositions and kits comprising at least one nitric oxide enhancing angiotensin II antagonist compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing angiotensin II antagonist compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (1) treating peripheral vascular diseases; (m) treating portal hypertension (o) treating central nervous system disorders; (p) treating metabolic syndrome; and (q) treating hyperlipidemia. The nitric oxide enhancing angiotensin II antagonist compounds comprise at least one nitric oxide enhancing group linked to the angiotensin II antagonist compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

    NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    7.
    发明公开
    NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
    NITRO镀锌GLUTAMINSÄUREVERBINDUNGEN，组合物和应用过程

    公开(公告)号：EP1673384A2

    公开(公告)日：2006-06-28

    申请号：EP04784974.0

    申请日：2004-09-27

    申请人： Nitromed, Inc.

    发明人： GARVEY, David, S. ,  EARL, Richard, A. ,  EZAWA, Maiko ,  FANG, Xinqin ,  GASTON, Ricky, D. ,  KHANAPURE, Subhash, P. ,  LIN, Chia-En ,  RANATUNGE, Ramani, R. ,  STEVENSON, Cheri, A. ,  WEY, Shiow-Jyi

    IPC分类号： C07K5/06

    CPC分类号： C07C271/22 ,  C07C229/24 ,  C07C237/12 ,  C07D295/185

    摘要： The invention describes novel nitrosated glutamic acid compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated glutamic acid compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated glutamic acid compound, and, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (1) treating diseases resulting from elevated levels of gamma-glutamyl transpeptidase and (m) the targeted delivery of compounds and nitric oxide to organs, cells or tissues containing the enzyme gamma-glutamyl transpeptidase.